VANGUARD GROUP INC 13D and 13G filings for Amylyx Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 1:22 pm Unchanged | 2024-09-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VANGUARD GROUP INC | 3,089,645 4.530% | 0 (Unchanged) | Filing |
| 2024-11-04 10:56 am Sale | 2024-09-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VANGUARD GROUP INC | 3,089,645 4.530% | -2,185,921 (-41.43%) | Filing |
| 2024-02-13 4:58 pm Purchase | 2023-12-29 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VANGUARD GROUP INC | 5,275,566 7.810% | 917,074 (+21.04%) | Filing |
| 2023-02-09 11:07 am Purchase | 2022-12-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VANGUARD GROUP INC | 4,358,492 6.580% | 4,358,492 (New Position) | Filing |